Inquiry Basket
Loading ......
Filter By Product Search for
KNG1
KNG1 Full Name
kininogen 1
KNG1 Introduction
KNG1 (kininogen 1) gene encodes a key plasma protein precursor that plays a central role in the kallikrein–kinin system, a biochemical pathway that regulates inflammation, vascular permeability, and blood coagulation. KNG1 produces both high-molecular-weight kininogen (HMWK) and low-molecular-weight kininogen (LMWK) through alternative processing, serving as essential cofactors in contact activation pathways of coagulation. Researchers and clinicians have increasingly focused on KNG1 because dysregulation of the kinin–kallikrein system is linked to complex clinical challenges such as inflammatory disorders, vascular dysfunction, and coagulation abnormalities. Understanding KNG1 is particularly important for scientists studying the molecular mechanisms behind edema formation, thrombosis risk, and inflammatory signaling, as the protein functions as both a precursor of bioactive peptides like bradykinin and a scaffold that coordinates multiple protease interactions within plasma.
Functionally, KNG1 is deeply involved in regulating vascular tone, immune signaling, and proteolytic cascades. When cleaved by plasma kallikrein, KNG1 releases bradykinin, a potent vasoactive peptide that mediates vasodilation, increased vascular permeability, and inflammatory responses. Through this mechanism, KNG1 participates in host defense and tissue injury responses but also contributes to pathological inflammation when excessively activated. Beyond its classical role in the coagulation contact system involving factors such as factor XII and prekallikrein, emerging research has revealed broader regulatory networks in which KNG1 interacts with multiple signaling pathways. Recent studies have highlighted regulatory axes involving non-coding RNAs, including the LINC01018/miR-942-5p/KNG1 pathway, demonstrating that KNG1 expression can influence tumor cell proliferation, migration, and invasion. Additionally, bioinformatic and experimental analyses have suggested connections between KNG1 and major oncogenic signaling pathways, including EGFR-related networks, indicating that KNG1 may serve as a molecular node linking inflammatory signaling with cancer-associated pathways.
Growing evidence also connects KNG1 to a wide spectrum of human diseases, expanding its significance beyond hemostasis. Genetic studies have identified pathogenic variants in the KNG1 gene that cause severe high-molecular-weight kininogen deficiency, a rare condition associated with abnormal coagulation profiles and bleeding tendencies. Such mutations can disrupt the kallikrein–kinin system and contribute to disorders including hereditary angioedema-like syndromes and other vascular abnormalities. In oncology research, altered KNG1 expression has been reported in cancers such as glioma and glioblastoma, where it may influence tumor progression, microenvironmental signaling, and metabolic reprogramming. Proteomic studies further reveal that KNG1 interacts with proteins involved in immune regulation and metabolism, suggesting a role in tumor immunity and systemic inflammatory responses. Because of these diverse biological functions and disease associations, KNG1 is increasingly investigated as a potential biomarker and therapeutic target in fields ranging from coagulation disorders and inflammatory diseases to cancer biology, making it a critical molecule for researchers seeking to understand the interface between vascular biology, immunity, and tumor development.
Alternate Names for KNG1
KNG1; kininogen 1; BK; BDK; KNG; kininogen-1; HMWK; bradykinin; fitzgerald factor; high molecular weight kininogen; alpha-2-thiol proteinase inhibitor; williams-Fitzgerald-Flaujeac factor;
Loading ......
